Heat Biologics, Inc Earning Date (HTBX)

USA |NASDAQ |USD

HTBX Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Mar 25, 2022 (est) Dec 31, 2021 - - $-0.09
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Mar 25, 2022 (est) Dec 31, 2021 - - $603.19K

Heat Biologics, Inc's next estimated earnings date (based on same quarter last year's date) is Mar 25, 2022 for the fiscal quarter ending Dec 31, 2021.

HTBX Earnings Date & History Chart

HTBX Earnings & Revenue Forecast

HTBX Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 5 $-1.22 $-1.53 $-1.05

HTBX Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 0 $-1.22 $-1.22 $-1.17

HTBX Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 6 $330.00K $0.00 $2.00M

HTBX Earnings Date & Revenue History

HTBX Earnings History

|
Show More
Show More

HTBX Revenue History

|
Show More
Show More

Heat Biologics, Inc Next Earnings Date & Report

HTBX Nov 2021 (FQ) Earnings Date & Report Preview

HTBX's next estimated earnings date (based on same quarter last year's report date) is Mar 25, 2022 for the fiscal quarter ending Dec 31, 2021.

Heat Biologics, Inc Previous Earnings Dates & Reports

HTBX Previous Earnings Date & Report Recap: Sep 2021 (FQ)

Heat Biologics, Inc's previous earnings date was Nov 8, 2021 for its fiscal quarter ended Sep 30, 2021.

HTBX Previous Earnings Date & Report Recap: Dec 2020 (FY)

Heat Biologics, Inc's previous annual earnings date was Mar 25, 2021 for its fiscal year ended Dec 31, 2020.

HTBX's earnings per share (EPS) was $-1.63, missing the consensus analysts forecast of $-0.99 by 64.65% , and higher than the previous year's EPS (Dec 2019) by -60.53%.

Revenues were $2.95M, worse than the forecast of $2.95M by -0.00%, and down by -3.32% from previous year's revenue.

The company reported a net income of $-26.05M.

Heat Biologics, Inc reported a free cash flow of $-22.36M for its fiscal year, compared to $-13.10M a year ago.

The company ended the fiscal year with $1.85M in total debt, a decrease of -4.12% compared to the previous year.